Mebias Discovery Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$631K
- Investors
-
8
Mebias Discovery General Information
Description
Developer of pathway-selective drugs intended to identify molecules to bind G-protein coupled receptors to eliminate adverse effects that limit therapeutic index. The company offers a validated and efficient drug discovery technology with well-established mechanisms that presents a unique opportunity with lower risk than utilizing traditional techniques to explore new, non-validated mechanisms, enabling healthcare service providers to treat diseases related to neuroscience/pain, metabolic, gastroparesis, and inflammatory-related disorders.
Contact Information
Website
www.mebiasdiscovery.comCorporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Corporate Office
- 3675 Market Street
- Suite 200
- Philadelphia, PA 19104
- United States
Mebias Discovery Timeline
Mebias Discovery Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A1) | 23-Sep-2022 | $631K | Completed | Clinical Trials - Phase 1 | ||
| 5. Grant | 10-Jan-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 29-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 14-Oct-2019 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 24-Sep-2018 | $10M | Completed | Pre-Clinical Trials | ||
| 1. Grant | 15-Sep-2018 | $2M | Completed | Pre-Clinical Trials |
Mebias Discovery Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Mebias Discovery Comparisons
Industry
Financing
Details
Mebias Discovery Competitors (3)
One of Mebias Discovery’s 3 competitors is Confo Therapeutics, a Venture Capital-Backed company based in Ghent, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Confo Therapeutics | Venture Capital-Backed | Ghent, Belgium | ||||
| Escient Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Domain Therapeutics | Venture Capital-Backed | Illkirch, France |
Mebias Discovery Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mebias Discovery Patents
Mebias Discovery Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2018211057-A1 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Active | 17-Jan-2017 | ||
| AU-2018211057-B2 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Active | 17-Jan-2017 | ||
| CA-3050515-A1 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Pending | 17-Jan-2017 | ||
| EP-3570838-A1 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Active | 17-Jan-2017 | ||
| EP-3570838-A4 | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | Active | 17-Jan-2017 | C07D211/52 |
Mebias Discovery Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mebias Discovery Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Life Science Angels | Angel Group | Minority | ||
| Westfield BioVentures | Accelerator/Incubator | Minority | ||
| National Institutes of Health | Government | |||
| Ben Franklin Technology Partners of Southeastern Pennsylvania | Accelerator/Incubator | Minority | ||
| BioAdvance Capital (Conshohocken) | Venture Capital | Minority |
Mebias Discovery FAQs
-
When was Mebias Discovery founded?
Mebias Discovery was founded in 2015.
-
Where is Mebias Discovery headquartered?
Mebias Discovery is headquartered in Philadelphia, PA.
-
What is the size of Mebias Discovery?
Mebias Discovery has 4 total employees.
-
What industry is Mebias Discovery in?
Mebias Discovery’s primary industry is Drug Discovery.
-
Is Mebias Discovery a private or public company?
Mebias Discovery is a Private company.
-
What is the current valuation of Mebias Discovery?
The current valuation of Mebias Discovery is .
-
What is Mebias Discovery’s current revenue?
The current revenue for Mebias Discovery is .
-
How much funding has Mebias Discovery raised over time?
Mebias Discovery has raised $4.13M.
-
Who are Mebias Discovery’s investors?
Life Science Angels, Westfield BioVentures, National Institutes of Health, Ben Franklin Technology Partners of Southeastern Pennsylvania, and BioAdvance Capital (Conshohocken) are 5 of 8 investors who have invested in Mebias Discovery.
-
Who are Mebias Discovery’s competitors?
Confo Therapeutics, Escient Pharmaceuticals, and Domain Therapeutics are competitors of Mebias Discovery.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
